Idorsia

Idorsia is a Swiss-based biopharmaceutical company founded on June 16, 2017, as a spinoff from Actelion Pharmaceuticals Ltd following Actelion's acquisition by Johnson & Johnson for approximately $30 billion. Incorporated in March 2017 and listed on the SIX Swiss Exchange in June 2017, Idorsia retained Actelion's drug discovery operations, early-stage clinical development assets, and scientific expertise. The company is headquartered in Allschwil, near Basel, Switzerland—the same location where Actelion was originally founded. Johnson & Johnson invested CHF 1 billion for a 16% equity stake, providing critical initial capital. Under the leadership of founders Jean-Paul Clozel (CEO and now Chairman) and Martine Clozel (Chief Scientific Officer), Idorsia began operations with approximately 650 employees and a CHF 1 billion cash reserve. The separation from Actelion was complex, requiring the transfer of 40,000 contracts and resolution of critical issues including intellectual property access, scientific databases, and IT infrastructure. As of September 30, 2025, Idorsia reported trailing 12-month revenue of $273 million, reflecting commercial success of its marketed products and expanding international presence.

Idorsia has two marketed pharmaceutical products. QUVIVIQ (daridorexant) is approved for the treatment of insomnia disorder in adult patients and is available in multiple markets including the United States, Canada, Europe, Japan, Hong Kong, and China. Daridorexant is a selective dual orexin receptor antagonist that promotes sleep by blocking wake-promoting neurotransmitters. QUVIVIQ sales more than doubled in 2025, demonstrating strong commercial momentum and market adoption. TRYVIO (US designation) and JERAYGO (European designation, aprocitentan) is a non-peptide endothelin receptor antagonist indicated for resistant hypertension. The company is actively expanding the daridorexant development program into pediatric populations, having announced positive Phase II results in March 2026 for children aged 10 to under 18 years with insomnia disorder. These results demonstrated statistically significant dose-dependent improvements in total sleep time with excellent safety and tolerability, opening potential new therapeutic indications in pediatric and neurodevelopmental populations. Both products are marketed through direct commercial operations and regional partnership agreements, allowing Idorsia to maximize market penetration while leveraging partner expertise for regional development and distribution.

Idorsia maintains a diversified pipeline across multiple therapeutic areas with several near-term clinical catalysts expected through 2026 and beyond. The lead catalyst was the March 2026 announcement of positive Phase II results for daridorexant in pediatric insomnia, demonstrating statistically significant dose-dependent improvements in total sleep time. The company plans to engage with health authorities to discuss next steps in pediatric development and explore daridorexant's potential in pediatric neurodevelopmental disorders. Lucerastat is advancing in registration studies for Fabry disease and other lysosomal storage disorders, with registration data expected within 2026. Through the March 2024 Viatris collaboration, cenerimod and selatogrel are being advanced globally with multiple development and regulatory milestones anticipated. Cenerimod is a selective S1P1 receptor modulator for immunological disease, while selatogrel is a P2Y12 receptor antagonist for cardiovascular indications. Additional Phase II programs span central nervous system, cardiovascular, and immunological indications, though timelines for these earlier-stage programs extend beyond 2026. The company's clinical development calendar provides multiple value-creation inflection points and opportunities for regulatory interactions that could drive commercial expansion of both marketed products and advance the next generation of Idorsia therapeutics to market.

Idorsia's executive leadership and board of directors combine extensive pharmaceutical industry experience with corporate governance expertise. Jean-Paul Clozel serves as Chairman of the Board and interim Chief Executive Officer (appointed March 2026). Clozel founded Actelion in 1997 and served as CEO from 2000 to 2017, bringing nearly three decades of pharmaceutical development experience. Martine Clozel, cofounder of Actelion, serves as Executive Vice President and Chief Scientific Officer, providing scientific direction and oversight of drug discovery and development programs. André C. Muller is Executive Vice President and Chief Financial Officer, responsible for financial planning, investor relations, and capital allocation. The Board of Directors includes Jean-Paul Clozel (Chairman), Mathieu Simon (Vice-Chairman and Lead Independent Director), Srishti Gupta (Executive Board member), Bart Filius (Chair of the Nominating, Governance and Compensation Committee), and Sandy Mahatme (Chair of the Finance and Audit Committee). This board composition balances entrepreneurial leadership experience with independent oversight functions appropriate for a publicly traded biopharmaceutical company, ensuring effective governance while maintaining strategic continuity with Actelion's pharmaceutical development heritage.

Idorsia has established multiple strategic partnerships to accelerate development, expand commercialization, and maximize pipeline value. The most significant recent partnership is with Viatris (announced March 2024), providing Idorsia $350 million upfront and up to $200 million in development contributions for global development and commercialization rights to selatogrel and cenerimod, with tiered royalties on net sales. In February 2025, Idorsia and Viatris updated terms with Idorsia receiving a $100 million reduction in development cost obligations. For QUVIVIQ (daridorexant) commercialization, Idorsia maintains regional partnerships including Syneos Health (United States—expanded agreement for sales force operations), Simcere (Greater China—exclusive licensing for Mainland China, Hong Kong, Macau), EMS (Latin America—licensing and supply agreement with $20 million milestone payments and double-digit royalties), and CTS (Israel). Additional partnerships include reacquisition of aprocitentan rights from Janssen (September 2023), vamorolone licensing and royalty monetization with ReveraGen BioPharma and Santhera Pharmaceuticals, and a December 2024 royalty monetization agreement with R-Bridge Healthcare Fund for $30 million regarding future vamorolone royalties and milestones. These partnerships provide capital, development support, regional market access, and commercial infrastructure while allowing Idorsia to maintain focused research and development operations in Switzerland.

Idorsia was created as a spinoff from Actelion Pharmaceuticals Ltd following Actelion's acquisition by Johnson & Johnson for approximately $30 billion in 2017. Actelion was founded in 1997 by Jean-Paul Clozel and Martine Clozel and became a leading Swiss biopharmaceutical company focused on small-molecule discovery and development. When Johnson & Johnson completed the Actelion acquisition on June 12, 2017, the parties had agreed to create a new company, Idorsia, to retain Actelion's drug discovery operations and early-stage clinical development assets. Idorsia was incorporated in March 2017 and began trading on the SIX Swiss Exchange in June 2017. The founders, Jean-Paul and Martine Clozel, led the spinoff effort and continued as Idorsia's leadership team. Idorsia operates on the same campus in Allschwil, Basel where Actelion was originally founded, maintaining institutional continuity and access to scientific expertise. Johnson & Johnson invested CHF 1 billion for a 16% equity stake in Idorsia, providing critical initial capital and demonstrating confidence in the spinoff strategy. The separation was complex, requiring the transfer of 40,000 contracts and resolution of issues including intellectual property access, scientific databases, and information technology infrastructure. Idorsia inherited the scientific reputation and drug discovery culture of Actelion while establishing itself as an independent biopharmaceutical company.

Idorsia focuses development efforts on four primary therapeutic areas: central nervous system disorders, cardiovascular disease, immunological disease, and orphan disease. This therapeutic portfolio reflects a strategic commitment to addressing significant unmet medical needs across diverse patient populations with a focus on small-molecule innovation. In central nervous system indications, the company's lead program is daridorexant (QUVIVIQ) for insomnia disorder, now expanded into pediatric populations following positive Phase II results announced in March 2026. The company is exploring daridorexant potential in pediatric neurodevelopmental disorders. The cardiovascular program centers on aprocitentan (TRYVIO/JERAYGO), a non-peptide endothelin receptor antagonist approved for resistant hypertension. The immunological disease focus includes cenerimod, a selective S1P1 receptor modulator, and selatogrel, a P2Y12 receptor antagonist, both advancing through the Viatris partnership. The orphan disease program includes lucerastat, advancing in registration studies for Fabry disease and other lysosomal storage disorders. Idorsia's development strategy emphasizes small-molecule therapeutics with clear mechanisms of action, well-defined regulatory pathways, and significant commercial potential. This focused approach allows the company to leverage its specialized scientific capabilities while maintaining development efficiency and advancing programs toward regulatory approval and commercial launch within its targeted therapeutic areas.